VGAIT for Chemotherapy-induced Peripheral Neuropathy

Inclusion Criteria: * at least 18 years of age * have histologically confirmed stage I-III breast cancer, * have completed adjuvant taxane-based chemotherapy (alone or in combination), , * have an Eastern Cooperative Oncology Group performance status of 0 or 1, and reported grade 1 or greater CIPN symptoms for more than 2 weeks as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Exclusion Criteria: * concurrent chemotherapy (there were no limitations on time from the last paclitaxel administration), * having metastatic or recurrent disease, * history of preexisting peripheral neuropathy prior to chemotherapy, * uncontrolled seizure disorder, * unstable cardiac disease or myocardial infarction within 6 months prior to study entry, being pregnant or nursing, or having used acupuncture for CIPN within 6 months prior to study entry.